A Phase 3 interventional study of Risperidone ISM 75 mg and Risperidone ISM 100 mg in Schizophrenia, sponsored by Rovi Pharmaceuticals Laboratories. Completed at 24 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-03-25.
Sponsored by Rovi Pharmaceuticals Laboratories · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.
Among the 127 studies testing risperidone in Schizophrenia, this one is the 34th largest by enrollment of the 123 interventional ones that give a count, is one of 3 that started in 2017, is one of 34 in phase 3, and was the 115th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
Louisiana State University Health Sciences Center Shreveport · Sites in United States
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
By country, each count listing its studies:
Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 7 · Phase 3 34 · Phase 4 63
First in 1996; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 215 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 100 across the 123 interventional studies. Of the 106 that completed or were terminated, 30 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 127 have an industry lead sponsor. The 10 most frequent:
Rovi Pharmaceuticals Laboratories is the lead sponsor of 19 studies on the registry; 2 are open to participants now.
Rovi Pharmaceuticals Laboratories has 8 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
2 of the studies testing risperidone in Schizophrenia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 127 studies testing risperidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is the long-term open label extension (OLE) of the study PRISMA-3 (NCT03160521). Those patients who complete participation in the main segment of the study (double blind) together with other clinically stable not previously enrolled (de novo patients) may opt to participate in this extension segment, where they will receive active Risperidone ISM® (75 mg or 100 mg)under open-label conditions every four weeks for approximately 12 months.
Patients who have completed planned participation in the double-blind segment of the study PRISMA-3 (NCT03160521) through to the end of the treatment period, may be eligible to enter into this optional long-term extension segment of the study. During this extension, open-label Risperidone ISM® (i.e., either 75 or 100 mg) will be administered to all participating patients once every 4 weeks for approximately 12 months. Patients who enter into the extension segment of the study will begin participation in the extension segment immediately upon completion of the end-of-treatment visit assessments and procedures.
In addition to patients continuing from the double-blind segment of the study PRISMA-3 (rollover patients), clinically stable patients not previously enrolled in the study (de novo patients) may be eligible to enter the long-term extension segment of the study. These patients will be evaluated for eligibility at a screening visit and, if eligible, will be allocated to receive either 75 or 100 mg Risperidone ISM every 4 weeks for approximately 12 months.
Approximately 100 de novo patients are planned to be enrolled in the extension segment of the study, in addition to rollover patients.
Participation in the open-label extension segment of the study PRISMA-3 is optional, and patients who complete participation in the main segment of the study (double blind segment of PRISMA-3, NCT03160521) may opt to not participate. Patients who are interested in participating must meet all eligibility criteria in order to enter into the extension segment.
Inclusion Criteria (Rollover patients):
To be eligible for entry into the extension segment of the study PRISMA-3, a patient must meet all of the following criteria at the extension baseline time point (immediately upon completion of the end-of-treatment visit assessments and procedures for the main part of the study):
Is willing to participate in the extension segment of the study and remains capable of providing
a. A signed informed consent form must be provided before any study assessments are performed for the extension segment
Exclusion Criteria (Rollover patients):
An individual who meets any of the following criteria at the extension baseline time point (immediately upon completion of the end-of-treatment visit assessments and procedures for the double blind segment PRISMA-3) will not be permitted to enter into this extension segment of the study PRISMA-3:
Inclusion Criteria (De Novo Patients):
Current diagnosis of schizophrenia, according to the , Fifth Edition (DSM-5) criteria that is clinically stable as evidenced by:
Exclusion Criteria (De Novo Patients):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients assigned to this arm will receive 75 mg of Risperidone ISM during the open label extensión (OLE). Patients enter the study as rollover patients from the study NCT03160521, along with newly enrolled de novo patients.
Drug: Risperidone ISM 75 mg
Patients assigned to this arm will receive 100 mg of Risperidone ISM during the open label extensión (OLE). Patients enter the study as rollover patients from the study NCT03160521, along with newly enrolled de novo patients.
Drug: Risperidone ISM 100 mg
Monthly (once every 4 weeks) intramuscular (IM) injection in the gluteal or deltoid muscle.
Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
PANSS Total Score Mean Change From Baseline to Endpoint
The Positive and Negative Syndrome Scale (PANSS) is a 30-item clinician-rated instrument for assessing the symptoms of schizophrenia.The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 PANSS items and ranges from 30 to 210, with 30 indicating absence of symptoms of schizophrenia and 210 indicating extreme ratings of all 30 symptoms. Negative change from baseline scores indicates improvements in symptoms whereas higher scores mean a worse outcome. Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation.
Time frame: Baseline and Day 365 (or the last post-baseline assessment)
PANSS Positive Subscale Mean Change From Baseline to Endpoint
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. PANSS Positive Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation.
Time frame: Baseline and Day 365 (or the last post-baseline assessment)
PANSS Negative Subscale Mean Change From Baseline to Endpoint
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated- absence of symptoms and a score of 7 indicated- extremely severe symptoms. The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs were: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. PANSS Negative Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation.
Time frame: Baseline and Day 365 (or the last post-baseline assessment)
PANSS General Psychopathology Subscale Mean Change From Baseline to Endpoint
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. The general psychopathology scale consists of 16 items which measure somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation and active social avoidance. PANSS General Psychopathology Subscale Score ranges from 16 (absence of symptoms) to 112 (extremely severe symptoms). Endpoint is defined as study day 356 or the last post-baseline assessment if early discontinuation.
Time frame: Baseline and Day 365 (or the last post-baseline assessment)
Clinician Global Impression - Severity (CGI-S) Total Score Mean Change From Baseline to Endpoint
The Clinician Global Impression - Severity (CGI-S) score is a 7-point clinician-rated scale for assessing the global severity of the illness. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Negative change from baseline scores indicate improvement in the severity of illness whereas higher scores mean a worse outcome. Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation.
Time frame: Baseline and Day 365 (or the last post-baseline assessment)
Clinician Global Impression - Improvement (CGI-I) Score
The Clinical Global Impression - Improvement (CGI-I) is a single 7-point rating score total improvement, regardless of whether or not the change it is due entirely to drug treatment. Raters select one response based on the following question, "Compared to your patient's condition at the beginning of treatment, how much has your patient changed?" Scores are: 1, Very much improved; 2, Much improved; 3, Minimally improved; 4, No change; 5, Minimally worse; 6, Much worse; or 7, Very much worse. Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation.
Time frame: Day 365 (or the last post-baseline assessment)
Overall Response Rate at Endpoint
Overall response was defined as either PANSS total score ≥ 30% decrease from baseline, or CGI-I score of 2 (much improved) or 1 (very much improved). Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation.
Time frame: Day 365 (or the last post-baseline assessment)
Relapse Rate
Relapse was defined as either increase from baseline in PANSS total score ≥30% or rehospitalization for psychotic symptoms or use of adjunctive antipsychotic medication after stabilization.
Time frame: Day 365 (or the last post-baseline assessment)
Patients With Treatment Emergent Adverse Events (TEAEs)
An Adverse event (AE) is any symptom, physical sign, syndrome, or disease that either emerges during the study (from the informed consent form signature) or, if present at screening, worsens during the study, regardless of the suspected cause of the event. The treatment-emergent AEs (TEAEs) are defined as events that are newly occurring or worsening from the time of the first dose of the intramuscular study drug.
Time frame: Up to Day 365 (or the last post-baseline assessment)
TEAEs Leading to Study Drug Discontinuation
TEAEs which resulted in permanent study drug discontinuation
Time frame: Up to Day 365 (or the last post-baseline assessment)
Patients With Treatment-related TEAEs
An Adverse event (AE) is any symptom, physical sign, syndrome, or disease that either emerges during the study (from the informed consent form signature) or, if present at screening, worsens during the study, regardless of the suspected cause of the event. The treatment-emergent AEs (TEAEs) are defined as events that are newly occurring or worsening from the time of the first dose of the intramuscular study drug. The temporal relationship of the AE with the investigational medicinal product makes causality possible, and the AE cannot be due to another cause such as other drugs, a surgical intervention, or an underlying disease
Time frame: Up to Day 365 (or the last post-baseline assessment)
Patients enter the study as rollover patients from the previous double-blind (DB) study (NCT03160521), along with newly enrolled de novo patients. Rollover patients received Risperidone ISM in the OLE study at the same dose as during the DB study (75 mg or 100 mg). Patients who received placebo in the DB were assigned to receive either Risperidone ISM 75 or 100 mg during the OLE. De novo patients received either Risperidone ISM 75 or 100 mg depending on the previous oral risperidone treatment.
| Milestone | Rollover Placebo/Risperidone ISM 75 mg | Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | De Novo/Risperidone ISM 75mg | Rollover Placebo/Risperidone ISM 100 mg | Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | De Novo/Risperidone ISM 100 mg |
|---|---|---|---|---|---|---|
| Started | 27 | 58 | 31 | 28 | 61 | 10 |
| Completed | 21 | 43 | 26 | 20 | 44 | 7 |
| Not completed | 6 | 15 | 5 | 8 | 17 | 3 |
The Positive and Negative Syndrome Scale (PANSS) is a 30-item clinician-rated instrument for assessing the symptoms of schizophrenia.The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 PANSS items and ranges from 30 to 210, with 30 indicating absence of symptoms of schizophrenia and 210 indicating extreme ratings of all 30 symptoms. Negative change from baseline scores indicates improvements in symptoms whereas higher scores mean a worse outcome. Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation.
| units on a scale | Rollover Placebo/Risperidone ISM 75 mg | Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | De Novo/Risperidone ISM 75mg | Rollover Placebo/Risperidone ISM 100 mg | Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | De Novo/Risperidone ISM 100 mg |
|---|---|---|---|---|---|---|
| PANSS Total Score Mean Change From Baseline to Endpoint | -22.9 ± 14.15 | -11.0 ± 14.52 | -0.8 ± 9.39 | -18.9 ± 14.61 | -8.7 ± 13.29 | -4.8 ± 4.80 |
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. PANSS Positive Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation.
| units on a scale | Rollover Placebo/Risperidone ISM 75 mg | Rollover Risperidone 75 mg/Risperidone 75 mg | De Novo/Risperidone ISM 75 mg | Rollover Placebo/Risperidone ISM 100 mg | Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | De Novo/Risperidone ISM 100 mg |
|---|---|---|---|---|---|---|
| PANSS Positive Subscale Mean Change From Baseline to Endpoint | -6.0 ± 4.84 | -3.3 ± 5.47 | -0.6 ± 3.32 | -6.5 ± 5.32 | -2.6 ± 4.75 | -1.6 ± 2.67 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated- absence of symptoms and a score of 7 indicated- extremely severe symptoms. The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs were: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. PANSS Negative Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation.
| units on a scale | Rollover Placebo/Risperidone ISM 75 mg | Risperidone ISM 75 mg/Risperidone ISM 75 mg | De Novo/Risperidone ISM 75 mg | Rollover Placebo/Risperidone ISM 100 mg | Risperidone ISM 100/Risperidone ISM 100 | De Novo/Risperidone ISM 100 mg |
|---|---|---|---|---|---|---|
| PANSS Negative Subscale Mean Change From Baseline to Endpoint | -4.6 ± 5.24 | -2.2 ± 3.61 | -0.3 ± 3.21 | -2.9 ± 3.75 | -2.1 ± 3.66 | -0.7 ± 4.22 |
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. The general psychopathology scale consists of 16 items which measure somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation and active social avoidance. PANSS General Psychopathology Subscale Score ranges from 16 (absence of symptoms) to 112 (extremely severe symptoms). Endpoint is defined as study day 356 or the last post-baseline assessment if early discontinuation.
| units on a scale | Rollover Placebo/Risperidone ISM 75 mg | Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | De Novo/Risperidone ISM 75mg | Rollover Placebo/Risperidone ISM 100 mg | Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | De Novo/Risperidone ISM 100 mg |
|---|---|---|---|---|---|---|
| PANSS General Psychopathology Subscale Mean Change From Baseline to Endpoint | -12.4 ± 8.33 | -5.4 ± 7.35 | 0.2 ± 5.73 | -9.4 ± 7.43 | -3.9 ± 7.37 | -2.5 ± 2.88 |
The Clinician Global Impression - Severity (CGI-S) score is a 7-point clinician-rated scale for assessing the global severity of the illness. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Negative change from baseline scores indicate improvement in the severity of illness whereas higher scores mean a worse outcome. Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation.
| units on a scale | Rollover Placebo/Risperidone ISM 75 mg | Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | De Novo/Risperidone ISM 75mg | Rollover Placebo/Risperidone ISM 100 mg | Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | De Novo/Risperidone ISM 100 mg |
|---|---|---|---|---|---|---|
| Clinician Global Impression - Severity (CGI-S) Total Score Mean Change From Baseline to Endpoint | -1.3 ± 1.02 | -0.5 ± 0.94 | 0.0 ± 0.53 | -1.0 ± 0.88 | -0.3 ± 0.80 | -0.1 ± 0.32 |
The Clinical Global Impression - Improvement (CGI-I) is a single 7-point rating score total improvement, regardless of whether or not the change it is due entirely to drug treatment. Raters select one response based on the following question, "Compared to your patient's condition at the beginning of treatment, how much has your patient changed?" Scores are: 1, Very much improved; 2, Much improved; 3, Minimally improved; 4, No change; 5, Minimally worse; 6, Much worse; or 7, Very much worse. Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation.
| score on a scale | Rollover Placebo/Risperidone ISM 75 mg | Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | De Novo/Risperidone ISM 75mg | Rollover Placebo/Risperidone ISM 100 mg | Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | De Novo/Risperidone ISM 100 mg |
|---|---|---|---|---|---|---|
| Clinician Global Impression - Improvement (CGI-I) Score | 2.3 ± 1.18 | 2.9 ± 1.14 | 3.7 ± 1.09 | 2.4 ± 0.92 | 2.9 ± 1.24 | 3.1 ± 1.10 |
Overall response was defined as either PANSS total score ≥ 30% decrease from baseline, or CGI-I score of 2 (much improved) or 1 (very much improved). Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation.
| percentage of participants | Rollover Placebo/Risperidone ISM 75 mg | Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | De Novo/Risperidone ISM 75mg | Rollover Placebo/Risperidone ISM 100 mg | Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | De Novo/Risperidone ISM 100 mg |
|---|---|---|---|---|---|---|
| Overall Response Rate at Endpoint | 74.1 (53.7 to 88.9) | 44.8 (31.7 to 58.5) | 9.7 (2.0 to 25.8) | 64.3 (44.1 to 81.4) | 45.9 (33.1 to 59.2) | 20.0 (2.5 to 55.6) |
Relapse was defined as either increase from baseline in PANSS total score ≥30% or rehospitalization for psychotic symptoms or use of adjunctive antipsychotic medication after stabilization.
| percentage of participants | Rollover Placebo/Risperidone ISM 75 mg | Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | De Novo/Risperidone ISM 75mg | Rollover Placebo/Risperidone ISM 100 mg | Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | De Novo/Risperidone ISM 100 mg |
|---|---|---|---|---|---|---|
| Relapse Rate | 11.1 (2.4 to 29.2) | 10.3 (3.9 to 21.2) | 12.9 (3.6 to 29.8) | 0 (0 to 0) | 13.1 (5.8 to 24.2) | 20.0 (2.5 to 55.6) |
An Adverse event (AE) is any symptom, physical sign, syndrome, or disease that either emerges during the study (from the informed consent form signature) or, if present at screening, worsens during the study, regardless of the suspected cause of the event. The treatment-emergent AEs (TEAEs) are defined as events that are newly occurring or worsening from the time of the first dose of the intramuscular study drug.
| Participants | Risperidone ISM 75 mg | Risperidone ISM 100 mg |
|---|---|---|
| Patients with at least one TEAE | 81 | 59 |
| Patients with at least one treatment-related TEAE | 43 | 41 |
| Patients with at least one serious TEAE | 6 | 5 |
| Patients with at least one TEAE leading to treatment discontinuation | 7 | 8 |
| Patients with at least one TEAE leading to death | 1 | 0 |
TEAEs which resulted in permanent study drug discontinuation
| Participants | Risperidone ISM 75 mg | Risperidone ISM 100 mg |
|---|---|---|
| Akathisia | 0 | 1 |
| Diabetes mellitus | 1 | 0 |
| Extrapyramidal disorder | 1 | 0 |
| Gynaecomastia | 0 | 1 |
| Hepatic Steatosis | 0 | 1 |
| Hepatocellular injury | 0 | 1 |
| Libido decreased | 1 | 0 |
| Schizophrenia | 2 | 5 |
| Suicidal ideation | 1 | 0 |
| Weight increased | 1 | 0 |
An Adverse event (AE) is any symptom, physical sign, syndrome, or disease that either emerges during the study (from the informed consent form signature) or, if present at screening, worsens during the study, regardless of the suspected cause of the event. The treatment-emergent AEs (TEAEs) are defined as events that are newly occurring or worsening from the time of the first dose of the intramuscular study drug. The temporal relationship of the AE with the investigational medicinal product makes causality possible, and the AE cannot be due to another cause such as other drugs, a surgical intervention, or an underlying disease
| Participants | Risperidone ISM 75 mg | Risperidone ISM 100 mg |
|---|---|---|
| Akathisia | 4 | 4 |
| Asthenia | 7 | 4 |
| Dizziness | 3 | 3 |
| Headache | 16 | 10 |
| Hyperprolactinemia | 11 | 10 |
| Insomnia | 6 | 3 |
| Weight increased | 6 | 3 |
Collected over Day 1 to week 52. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Risperidone ISM 75 mg | 1/116 (0.9%) | 6/116 (5.2%) | 81/116 (69.8%) |
| Risperidone ISM 100 mg | 0/99 (0%) | 5/99 (5.1%) | 59/99 (59.6%) |
| Event | Risperidone ISM 75 mg | Risperidone ISM 100 mg |
|---|---|---|
| SchizophreniaPsychiatric disorders | 3/116 | 4/99 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/116 | 1/99 |
| Intentional overdoseInjury, poisoning and procedural complications | 1/116 | 0/99 |
| Completed suicidePsychiatric disorders | 1/116 | 0/99 |
| InsomniaPsychiatric disorders | 1/116 | 0/99 |
| Suicidal ideationPsychiatric disorders | 1/116 | 0/99 |
| Event | Risperidone ISM 75 mg | Risperidone ISM 100 mg |
|---|---|---|
| HeadacheNervous system disorders | 24/116 | 18/99 |
| NasopharyngitisInfections and infestations | 13/116 | 9/99 |
| InsomniaPsychiatric disorders | 13/116 | 3/99 |
| HyperprolactinaemiaEndocrine disorders | 11/116 | 10/99 |
| Weight increasedInvestigations | 8/116 | 4/99 |
| AstheniaGeneral disorders | 7/116 | 4/99 |
| SchizophreniaPsychiatric disorders | 5/116 | 5/99 |
| DiarrhoeaGastrointestinal disorders | 5/116 | 1/99 |
| AkathisiaNervous system disorders | 4/116 | 4/99 |
| AnxietyPsychiatric disorders | 3/116 | 4/99 |
All analyses were undertaken on the population of patients who received at least one dose of study drug during the OLE study.
| Age, Continuous(years) | Rollover Placebo/Risperidone ISM 75 mg | Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | De Novo/Risperidone ISM 75mg | Rollover Placebo/Risperidone ISM 100 mg | Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | De Novo/Risperidone ISM 100 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 38.7 ± 9.29 | 40.9 ± 11.98 | 37.0 ± 10.91 | 38.4 ± 10.42 | 40.3 ± 11.04 | 35.5 ± 6.40 | 39.3 ± 10.84 |
| Sex: Female, Male(Participants) | Rollover Placebo/Risperidone ISM 75 mg | Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | De Novo/Risperidone ISM 75mg | Rollover Placebo/Risperidone ISM 100 mg | Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | De Novo/Risperidone ISM 100 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 7 | 20 | 11 | 17 | 23 | 6 | 84 |
| Male | 20 | 38 | 20 | 11 | 38 | 4 | 131 |
| Ethnicity (NIH/OMB)(Participants) | Rollover Placebo/Risperidone ISM 75 mg | Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | De Novo/Risperidone ISM 75mg | Rollover Placebo/Risperidone ISM 100 mg | Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | De Novo/Risperidone ISM 100 mg | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 5 | 0 | 2 | 0 | 0 | 8 |
| Not Hispanic or Latino | 26 | 53 | 31 | 26 | 61 | 10 | 207 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Rollover Placebo/Risperidone ISM 75 mg | Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | De Novo/Risperidone ISM 75mg | Rollover Placebo/Risperidone ISM 100 mg | Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | De Novo/Risperidone ISM 100 mg | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 7 | 0 | 6 | 14 | 0 | 32 |
| White | 22 | 50 | 31 | 22 | 47 | 10 | 182 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Rollover Placebo/Risperidone ISM 75 mg | Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | De Novo/Risperidone ISM 75mg | Rollover Placebo/Risperidone ISM 100 mg | Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | De Novo/Risperidone ISM 100 mg | Total |
|---|---|---|---|---|---|---|---|
| United States | 7 | 11 | 0 | 6 | 16 | 0 | 40 |
| Ukraine | 20 | 47 | 31 | 22 | 45 | 10 | 175 |
| Body Mass Index (BMI)(Kg/m^2) | Rollover Placebo/Risperidone ISM 75 mg | Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | De Novo/Risperidone ISM 75mg | Rollover Placebo/Risperidone ISM 100 mg | Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | De Novo/Risperidone ISM 100 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 27.53 ± 4.488 | 26.52 ± 4.741 | 25.28 ± 3.695 | 27.65 ± 4.954 | 27.53 ± 5.055 | 26.06 ± 3.937 | 26.88 ± 4.685 |
| Years since Schizophrenia Diagnosis(years) | Rollover Placebo/Risperidone ISM 75 mg | Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | De Novo/Risperidone ISM 75mg | Rollover Placebo/Risperidone ISM 100 mg | Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | De Novo/Risperidone ISM 100 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 11.8 ± 6.81 | 12.1 ± 9.17 | 9.6 ± 8.12 | 9.3 ± 7.45 | 11.5 ± 7.98 | 6.4 ± 5.34 | 10.9 ± 8.09 |
| Time since Acute Exacerbation or relapse (weeks)(Weeks) | Rollover Placebo/Risperidone ISM 75 mg | Rollover Risperidone ISM 75mg/Risperidone ISM 75mg | De Novo/Risperidone ISM 75mg | Rollover Placebo/Risperidone ISM 100 mg | Rollover Risperidone ISM 100 mg/Risperidone ISM 100 mg | De Novo/Risperidone ISM 100 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 0.4 ± 0.18 | 0.3 ± 0.21 | 0 ± 0 | 0.4 ± 0.20 | 0.4 ± 0.24 | 0 ± 0 | 0.4 ± 0.21 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2017 to primary completion in Jan 2020, 28 months.
Results were first posted in Feb 2022, 2 years 1 month after primary completion. A results delay was requested in Nov 2020.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 28 months is below that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risperidone
Rovi Pharmaceuticals Laboratories